Arvinas Q1 net loss widens to $81.9M; vepdegestrant combo shows 60.7% CBR

ARVINAS, INC.

2023-Q1 EPS reported -$1.54 revenue$32,500,000

Net loss of $81.9M for Q1 2023 vs $63.4M in Q1 2022; revenue increased to $32.5M from $26.5M.
Cash, equivalents, and marketable securities of $1.129B, with expected runway into 2026.
R&D expenses rose to $95.3M (up 49% YoY) driven by increased pipeline investment and Pfizer cost sharing.
Vepdegestrant + palbociclib Phase 1b (Part C) showed 60.7% CBR in heavily pretreated ER+/HER2- mBC patients.
Plans to initiate Phase 3 safety lead-in for vepdegestrant + palbociclib in 1L mBC in 2H 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ARVINAS, INC. reported financial results for first quarter ended March 31, 2023.

Period: first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

announced its financial results for the quarter ended March 31, 2023

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

ARVINAS, INC. filing history →

Source: SEC EDGAR

accession 0001655759-23-000039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.